These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
431 related articles for article (PubMed ID: 16221425)
21. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122 [TBL] [Abstract][Full Text] [Related]
22. Radioimmunotherapy for B-cell non-Hodgkin lymphoma. Witzig TE Best Pract Res Clin Haematol; 2006; 19(4):655-68. PubMed ID: 16997175 [TBL] [Abstract][Full Text] [Related]
23. Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody. Tsai DE; Maillard I; Schuster SJ; Nasta SD; Porter DL; Klumpp TR; Goldenberg DM; Luger SM; Alavi A; Sharkey RM; Hartzell KB; Stadtmauer EA Clin Lymphoma; 2003 Jun; 4(1):56-9. PubMed ID: 12837157 [TBL] [Abstract][Full Text] [Related]
24. Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies. Kawashima H ScientificWorldJournal; 2014; 2014():492061. PubMed ID: 25379535 [TBL] [Abstract][Full Text] [Related]
25. How and why does radioimmunotherapy work? Macklis RM Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1269-71. PubMed ID: 15275708 [No Abstract] [Full Text] [Related]
26. Centralized radiolabeling of antibodies for radioimmunotherapy. Colcher D J Nucl Med; 1998 Aug; 39(8 Suppl):11S-13S. PubMed ID: 9708565 [TBL] [Abstract][Full Text] [Related]
27. Radioimmunotherapy and NHL: nuclear medicine on the oncology team. Knight N J Nucl Med; 2002 Apr; 43(4):11N-12N, 25N, passim. PubMed ID: 11963928 [No Abstract] [Full Text] [Related]
34. Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. Kaminski MS; Radford JA; Gregory SA; Leonard JP; Knox SJ; Kroll S; Wahl RL J Clin Oncol; 2005 Nov; 23(31):7985-93. PubMed ID: 16204016 [TBL] [Abstract][Full Text] [Related]
35. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. Witzig TE; White CA; Wiseman GA; Gordon LI; Emmanouilides C; Raubitschek A; Janakiraman N; Gutheil J; Schilder RJ; Spies S; Silverman DH; Parker E; Grillo-López AJ J Clin Oncol; 1999 Dec; 17(12):3793-803. PubMed ID: 10577851 [TBL] [Abstract][Full Text] [Related]
36. Successful autologous peripheral blood stem cell transplantation in transformed follicular lymphoma previously treated with radioimmunotherapy (iodine (131)I tositumomab). Cooney J; Stiff P; Kaminski M Bone Marrow Transplant; 2002 Mar; 29(6):523-5. PubMed ID: 11960274 [TBL] [Abstract][Full Text] [Related]
37. Targeting CD20 in follicular NHL: novel anti-CD20 therapies, antibody engineering, and the use of radioimmunoconjugates. Leonard JP Hematology Am Soc Hematol Educ Program; 2005; ():335-9. PubMed ID: 16304400 [TBL] [Abstract][Full Text] [Related]
38. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016 [TBL] [Abstract][Full Text] [Related]
40. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study. Cooney-Qualter E; Krailo M; Angiolillo A; Fawwaz RA; Wiseman G; Harrison L; Kohl V; Adamson PC; Ayello J; vande Ven C; Perkins SL; Cairo MS; Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5652s-5660s. PubMed ID: 17875803 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]